NEW YORK — Abcam said on Monday that it has expanded its cancer diagnostics development alliance with China's MEDx Translational Medicine.
In 2018, Abcam began working with MEDx — then known as Qiagen Translational Medicine — to develop companion diagnostic and in vitro diagnostic reagents and kits targeting the cancer genes pan-NTRK and dMMR, as well as certain other protein-based companion diagnostic products.
According to UK-based Abcam, the companies will now collaborate to define additional targets for diagnostic products in certain other indications for the Chinese market. Abcam will provide MEDx with validated specific antibodies and help it create novel binders as required. MEDx will use these resources to develop immunoassay-based companion and in vitro diagnostic products for commercialization.
Additional terms were not disclosed.
"We are looking forward to combining our end-to-end capabilities to identify and develop high-quality recombinant monoclonal antibodies with MEDx's companion diagnostics development experience," John Baker, senior VP of business development at Abcam, said in a statement.
In late 2019, MEDx formed a cancer companion diagnostics development alliance with Lucence Diagnostics. In mid-2020, Abcam began working with Cancer Research UK to develop custom antibodies for research and diagnostic development applications.